Global Alcohol Dependency Treatment Market Growth (Status and Outlook) 2023-2029

Global Alcohol Dependency Treatment Market Growth (Status and Outlook) 2023-2029

The global Alcohol Dependency Treatment market size is projected to grow from US$ 526.3 million in 2022 to US$ 1446.6 million in 2029; it is expected to grow at a CAGR of 15.5% from 2023 to 2029.

The key manufacturers of alcohol dependency treatment in the world include Alkermes Inc, Merck Group, Lundbeck, Alvogen, Mylan, Teva, Sun Pharmaceutical Industries, Zydus Pharmaceuticals, Taj Pharmaceuticals and TAGI Pharma Inc., among which the top five manufacturers account for nearly 75% of the market share. The largest manufacturer is Alkermes Inc., which has more than 40% market share. The global alcohol dependency treatment market is mainly distributed in North America, Central Europe and Western Europe, Asia-Pacific region and Northern Europe, among which the first two markets account for more than 70% of the market share. At present, North America is the largest market, accounting for more than 45% of the market share, followed by Central Europe and Western Europe. As far as products are concerned, the relative growth rate of naltrexone is faster, with more than 60% of the market share at present, followed by acamprosate. In terms of application, hospital is the largest application field, accounting for more than 30% of the market share, followed by rehabilitation institutions and clinics.

LPI (LP Information)' newest research report, the “Alcohol Dependency Treatment Industry Forecast” looks at past sales and reviews total world Alcohol Dependency Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Alcohol Dependency Treatment sales for 2023 through 2029. With Alcohol Dependency Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Alcohol Dependency Treatment industry.

This Insight Report provides a comprehensive analysis of the global Alcohol Dependency Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Alcohol Dependency Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Alcohol Dependency Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Alcohol Dependency Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Alcohol Dependency Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Alcohol Dependency Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Naltrexone
Acamprosate
Disulfiram
Other

Segmentation by application
Hospital
Rehabilitation Institutions
Clinic
Retail Pharmacies

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alkermes Inc
Merck Group
Lundbeck
Alvogen
Mylan
Teva
Sun Pharmaceutical Industries
Zydus Pharmaceuticals
Taj Pharmaceuticals
TAGI Pharma Inc.
Beijing Wellso Pharmaceutical Co
Glenmark Pharmaceuticals
Rusan Pharma Ltd

Please note: The report will take approximately 2 business days to prepare and deliver.